Aquaporin-1 and sodium-hydrogen exchangers as pharmacological targets in diabetic atherosclerosis

Current Drug Targets

Volumn 16, Issue 4, 2015, Pages 361-365

  Madonna, Rosalinda ^a   De Caterina, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aquaporins; Atherosclerosis; Diabetes; Hyperosmolar stress; Sodium hydrogen exchangers

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMILORIDE; AQUAPORIN 1; CARIPORIDE; CYCLOOXYGENASE 2; DIMETHYL SULFOXIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INORGANIC SALT; INTERLEUKIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYLGLUCOSAMINE; PROTEIN KINASE C; SILVER SALT; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ZONIPORIDE; AQP1 PROTEIN, HUMAN; CARDIOVASCULAR AGENT; CATION TRANSPORT PROTEIN; SLC9A1 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL VOLUME; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; GLUCOTOXICITY; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPEROSMOLALITY; NONHUMAN; PROTEIN EXPRESSION; VASCULAR DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETIC ANGIOPATHIES; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; OSMOREGULATION; SIGNAL TRANSDUCTION;

ANIMALS; AQUAPORIN 1; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CATION TRANSPORT PROTEINS; DIABETIC ANGIOPATHIES; HUMANS; MOLECULAR TARGETED THERAPY; OSMOREGULATION; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER;

EID: 84928889702     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666141219115720     Document Type: Article

References (38)

1. [1] Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
2. [2] Merimee TJ. Diabetic retinopathy. A synthesis of perspectives. N Engl J Med 1990, 322: 978-83.
3. [3] Zatz R, Brenner BM. Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am J Med 1986; 80: 443-53.
4. [4] Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-8.
5. [5] Ahern J, Grove N, Strand T, Wesche J, Seibert C, Brenneman AT, Tamborlane WV. The impact of the Trial Coordinator in the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes Educ 1993; 19(6): 509-12.
6. [6] UK Prospective Diabetes Study (UKPDS) Group: Intensive blood- glucose control with sulphonylureas or insulin compared with con- ventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-53.
7. [7] Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006; 55(12): 3556-65.
8. [8] Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643-53.
9. [9] Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348(23): 2294-303.
10. 10[] Ruiz J, Egli M, Gianinazzi F, Izzo F, Voeffray Favre AC, Rossi I, Bodenman P, [Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus]. Rev Med Suisse 2010; 6(252): 1176-8, 1180-1.
11. [11] Burg MB, Ferraris JD, Dmitrieva NI. Cellular response to hy-perosmotic stresses. Physiol Rev 2007; 87(4): 1441-74.
12. [12] Ferraris JD, Burg MB. Tonicity-regulated gene expression. Methods Enzymol 2007, 428: 279-96.
13. [13] Nath SK, Hang CY, Levine SA, et al. Hyperosmolarity inhibits the Na+/H+ exchanger isoforms NHE2 and NHE3: an effect opposite to that on NHE1. Am J Physiol 1996; 270(3 Pt 1): G431-441.
14. [14] Jenq W, Mathieson IM, Ihara W, Ramirez G: Aquaporin-1: an osmoinducible water channel in cultured mIMCD-3 cells. Biochem Biophys Res Commun 1998; 245(3): 804-9.
15. [15] Fliegel L, Dyck JR. Molecular biology of the cardiac sodium/hydrogen exchanger. Cardiovasc Res 1995; 29(2): 155-9.
16. [16] Silva NL, Haworth RS, Singh D, Fliegel L. The carboxyl-terminal region of the Na+/H+ exchanger interacts with mammalian heat shock protein. Biochemistry 1995; 34(33):10412-20.
17. [17] Avkiran M, Marber MS. Na(+)/H(+) exchange inhibitors for car-dioprotective therapy: progress, problems and prospects. J Am Coll Cardiol 2002; 39(5): 747-53.
18. [18] Verkman AS: Aquaporins at a glance. J Cell Sci 2011; 124(Pt 13): 2107-12.
19. [19] Wakabayashi S, Shigekawa M, Pouyssegur J. Molecular physiology of vertebrate Na+/H+ exchangers. Physiol Rev 1997; 77(1): 51-74.
20. [20] Madonna R, De Caterina R, Cellular and Molecular Mechanisms of Vascular Injury in Diabetes Mellitus - Part I: Pathways of Vascular Disease in Diabetes. Vascul Pharmacol 2011; 54(3-6): 68-74.
21. [21] Karmazyn M. The sodium-hydrogen exchange system in the heart: its role in ischemic and reperfusion injury and therapeutic implications. Can J Cardiol 1996, 12(10): 1074-82.
22. [22] Madonna R, Montebello E, Zurro M, Lazzerini G, De Caterina R. Na+/H+ exchanger 1- and aquaporin-1-dependent hyperosmolary changes decrease nitric oxide production and induce VCAM-1 expression in endothelial cells exposed to high glucose. Int J Im-munopathol Pharmacol 2010; 23(3): 755-65.
23. [23] Shanahan CM, Connolly DL, Tyson KL, et al. Aquaporin-1 is expressed by vascular smooth muscle cells and mediates rapid water transport across vascular cell membranes. J Vasc Res 1999; 36(5): 353-62.
24. [24] Ennis IL, Garciarena CD, Escudero EM, et al. Normalization of the calcineurin pathway underlies the regression of hypertensive hypertrophy induced by Na+/H+ exchanger-1 (NHE-1) inhibition. Can J Physiol Pharmacol 2007; 85(3-4): 301-10.
25. [25] Wang SX, Sun XY, Zhang XH, Chen SX, Liu YH, Liu LY. Cari-poride inhibits high glucose-mediated adhesion of monocyte-endothelial cell and expression of intercellular adhesion molecule-1. Life Sci 2006; 79(14):1399-404.
26. [26] Sarigianni M, Tsapas A, Mikhailidis DP, Kaloyianni M, Koliakos G, Paletas K. Involvement of signaling molecules on na/h ex-changer-1 activity in human monocytes. Open Cardiovasc Med J 2010; 4: 181-8.
27. [27] Koliakos G, Zolota Z, Paletas K, Kaloyianni M. High glucose concentrations stimulate human monocyte sodium/hydrogen exchanger activity and modulate atherosclerosis-related functions. Pflugers Arch 2004; 449(3): 298-306.
28. [28] Sasahara T, Yayama K, Matsuzaki T, Tsutsui M, Okamoto H. Na(+)/H(+) exchanger inhibitor induces vasorelaxation through nitric oxide production in endothelial cells via intracellular acidification-associated Ca2(+) mobilization. Vascul Pharmacol 2013; 58(4): 319-25.
29. [29] Sasahara T, Yayama K, Tahara T, Onoe H, Okamoto H. Na+/H+ exchanger inhibitor augments hyperosmolarity-induced vasocon-striction by enhancing actin polymerization. Vascul Pharmacol 2013; 59(5-6): 120-6.
30. [30] Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9(6): 653-60.
31. [31] Fliegel L. Regulation of the Na(+)/H(+) exchanger in the healthy and diseased myocardium. Expert Opin Ther Targets 2009; 13(1): 55-68.
32. [32] Garcia-Dorado D, Gonzalez MA, Barrabes JA, et al. Prevention of ischemic rigor contracture during coronary occlusion by inhibition of Na(+)-H+ exchange. Cardiovasc Res 1997; 35(1): 80-9.
33. [33] Linz WJ, Busch AE. NHE-1 inhibition: from protection during acute ischaemia/reperfusion to prevention/reversal of myocardial remodelling. Naunyn Schmiedebergs Arch Pharmacol 2003; 368(4): 239-246.
34. [34] Karmazyn M, Sostaric JV, Gan XT. The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myo-cardial ischaemic and reperfusion injury and attenuation of postin-farction heart failure. Drugs 2001; 61(3): 375-89.
35. [35] Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 2000; 102(25): 3032-8.
36. [36] Rupprecht HJ, vom Dahl J, Terres W, et al. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 2000; 101(25): 2902-8.
37. [37] Mentzer RM, Jr., Bartels C, Bolli R, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 2008; 85(4): 1261-70.
38. [38] Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myo-cardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001; 38(6): 1644-50.